Table 1. Baseline Patient Demographic and Disease Characteristics.
| Characteristic | Vemurafenib (n = 371) |
|---|---|
| Age, mean (SD), y | 53.5 (13.8) |
| Male, n (%) | 229 (62) |
| ECOG PS, n (%) | |
| 0 | 162 (44) |
| 1 | 138 (37) |
| 2 | 59 (16) |
| 3 | 12 (3) |
| Metastatic melanoma stage, n (%) | |
| M1a | 33 (9) |
| M1b | 35 (9) |
| M1c | 277 (75) |
| Unresectable stage III | 24 (7) |
| Unknown | 2 (<1) |
| Brain metastases, n (%) | 109 (29) |
| Prior cancer therapy | |
| Systemic therapy, n (%) | 266 (72) |
| 1 Therapy | 75 (20) |
| 2 Therapies | 64 (17) |
| ≥3 Therapies | 127 (34) |
| No. prior systemic therapies, mean (SD) | 2.9 (2) |
| Radiotherapy, n (%) | 175 (47) |